Microbot Medical achieves 100% LIBERTY success rate in large-scale preclinical animal study with leading European physicians


Microbot Medical Co., Ltd.

Microbot Medical Co., Ltd.

A team of 6 leading European radiation oncologists used the LIBERTY® Surgical Robotic System to perform a total of 48 catheterizations.

HINGHAM, Mass., May 22, 2023 (Globe Newswire) — Microbot Medical Inc. (Nasdaq: MBOT), creator of LIBERTY® The Surgical Robotic System, the first disposable endovascular robotic system, today announced the successful completion of a large collaborative pre-clinical animal study conducted at a leading European-based research institute.

A team of six of Europe’s leading radiologists utilized the system, delivering a total of 48 catheters to pre-determined vascular targets including the liver, stomach, spleen, mesentery, kidney and distal branches of the hypogastric artery. He underwent treatment and reached a 100% success rate. intended target.

Based on real-time user feedback, interventional radiologists found the system intuitive and easy to set up and use, adding to the ability to remotely control the procedure via the LIBERTY Robotic System remote controller. Impressed.

“The results of the multi-day study continue to validate LIBERTY, and as we plan to enter the human clinical phase later in clinical trials, the continued adjustments we are making will help the system. “This is further evidence to support the safety and efficacy of the drug,” commented Dr. Eyal Morag, Chief Medical Officer.

“We believe this, along with other opportunities for peer-reviewed publications, demonstrate the significant benefits LIBERTY is expected to bring when it is commercialized, laying the groundwork to help accelerate its early adoption.” I believe,” added Dr. Eyal Morag.

In preparation for continued progress towards commercialization of the LIBERTY Surgical Robotic System, the company intends to conduct preclinical studies in the U.S. and other target markets, as well as conduct first human cases in markets outside the U.S. .

The 48 successful catheterizations are part of the company’s recent announcement of over 100.th Catheterization during multiple preclinical studies has a 95% success rate in reaching pre-determined vascular targets.

About Microbot Medical

Microbot Medical Inc. (NASDAQ: MBOT) is a preclinical medical device company specializing in innovative microrobotic technology to improve clinical outcomes for patients and enable accessibility through natural and artificial lumens within the human body. It aims to raise.
The LIBERTY robotic system improves the use of surgical robots in today’s endovascular procedures by eliminating the need for large, cumbersome and expensive capital equipment while reducing radiation exposure and physician burden. is intended for We believe the remote operation of the LIBERTY Robotic System may be the first system to democratize endovascular procedures.
For more information about Microbot Medical, please visit http://www.microbotmedical.com.

safe harbor

statements regarding future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, and other statements regarding future expectations, beliefs, goals, plans and prospects; description. These management statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal Securities Act. Any statement that is not historical fact (including, but not limited to, words such as “will,” “believe,” “plan,” “anticipate,” “anticipate,” “estimate,” etc.) not) are also considered to be the same. Forward-Looking Statements. Forward-looking statements may include, but are not limited to, market conditions, the risks inherent in the development and/or commercialization of LIBERTY, the results of studies used to evaluate LIBERTY, and the adequacy of our core business focus programs and cost reduction plans. including, but not limited to, risks and uncertainties; Sufficient conditions for the Company to continue to focus on its LIBERTY technology while seeking additional working capital; Clinicians may not be recruited, may not be recruited, or may experience uncertainty. results of preclinical and clinical trials or regulatory pathways and approvals; uncertainties arising from the COVID-19 pandemic; the need and ability to obtain future capital; maintain. Additional information regarding the risks faced by Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC) and can be found on the SEC’s website at www.sec. gov). Microbot Medical disclaims any intention or obligation to update these forward-looking statements, except as required by law.

Investor contact:

Michal Efrati
+972-(0)52-3044404
IR@microbotmedical.com



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *